Category Archives: People

Beats over Badges: Gen Z Ignites 2026 Summer Tourism Boom as “Graduation Music Festivals” Take Center Stage

NORCROSS, Ga., June 24, 2026 (GLOBE NEWSWIRE) — As the school year wraps up, the summer travel market has officially shifted into high gear, propelled by an unprecedented wave of fresh graduates. This year, Gen Z has profoundly reshaped the post-exam sightseeing tradition. Stepping away from conventional tour groups, they are flocking to live music […]

Atalan Launches Nurse Retention Platform Designed to Identify Risk Up to 12 Months in Advance

Built specifically for nursing, the platform extends Atalan’s proven Clinician Retention Intelligence platform to increase retention in healthcare’s largest clinical workforce PHILADELPHIA, June 25, 2026 (GLOBE NEWSWIRE) — Nurse burnout remains a significant challenge in the healthcare industry, with growing interest in tools that can help identify retention risk earlier. Atalan for Nursing is intended […]

Data Presented on Two-Year Proximal Neck Dynamics from First-in-Human Study of Abdominal Aortic Aneurysm Treatment

TEMPE, Ariz., June 25, 2026 (GLOBE NEWSWIRE) — Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational Nectero EAST® System. The study met safety endpoints, and AAA growth rates were significantly lower than expected through two years post-treatment. At […]

Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)

Under Veripure, Provectus is supplying qualified medical researchers with the same pharmaceutical grade rose bengal sodium API used in clinical trials. Veripure is also a quality benchmark, distinguishing program-associated medical research on PV-10 from research conducted using commercially sourced rose bengal of variable purity and uncharacterized content. Provectus has supplied PV-10 to independent researchers in […]

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 4th Annual […]

Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of Key Trial Results SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range […]

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements — HONG KONG and FLORHAM PARK, N.J., June 25, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from […]

TWL Introduces Virtual Tirzepatide Assessment Program for Eligible Weight-Management Patients

New digital-care process connects clinical evaluation, coverage assistance, pharmacy coordination and continuing provider support New York, NY, June 24, 2026 (GLOBE NEWSWIRE) — TWL today announced the introduction of a dedicated virtual assessment program for eligible patients seeking medical evaluation for tirzepatide-based weight-management treatment. The program creates a coordinated process beginning with an online health […]

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place […]

FitRx Introduces Streamlined Tirzepatide Evaluation and Care Program

New virtual-care process coordinates medical review, prescription support, insurance navigation and ongoing follow-up for eligible weight-management patients New York, NY, June 24, 2026 (GLOBE NEWSWIRE) — FitRx announced the introduction of a dedicated tirzepatide evaluation and care program within its online weight-management platform. The new program establishes a structured process for eligible patients interested in […]